FADS1 and obesity disorder: Therefore, we can assume that the observed reduction in intramuscular FADS1 and FADS2 expression is in line with the diminished AA concentration following the administration of CBG in obese rats points out the high therapeutic potential of CBG as a new class of drug useful in combating obesity-related complications.